We are live on ! Find out more
ASTX

ASTEX PHARMACEUTICALS, INC COM
ASTX

Delisted

ASTX was delisted on the 10th of October, 2013.

Back to rankings

120 hedge funds and large institutions have $214M invested in ASTEX PHARMACEUTICALS, INC COM in 2013 Q2 according to their latest regulatory filings, with 120 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more call options, than puts

Call options by funds: $9.83M | Put options by funds: $9.7M

Holders
120
Holders Change
+120
Holders Change %
–
% of All Funds
3.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
120
Increased
–
Reduced
–
Closed
–
Calls
$9.83M
Puts
$9.7M
Net Calls
+$126K
Net Calls Change
+$126K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
MWNA
76
Marshall Wace North America
New York
$218K +$285K +53,013 New
SKK
77
Shepherd Kaplan Krochuk
Massachusetts
$218K +$285K +53,042 New
WB
78
WesBanco Bank
West Virginia
$206K +$269K +50,000 New
PGFC
79
Peapack-Gladstone Financial Corp
New Jersey
$206K +$269K +50,000 New
PAM
80
Panagora Asset Management
Massachusetts
$194K +$254K +47,148 New
GC
81
Guggenheim Capital
Illinois
$192K +$250K +46,554 New
Tudor Investment Corp
82
Tudor Investment Corp
Connecticut
$175K +$230K +42,700 New
GCP
83
GSA Capital Partners
United Kingdom
$163K +$213K +39,542 New
Prudential Financial
84
Prudential Financial
New Jersey
$160K +$209K +38,934 New
U
85
UBS
Switzerland
$156K +$204K +37,987 New
Principal Financial Group
86
Principal Financial Group
Iowa
$153K +$200K +37,272 New
Citigroup
87
Citigroup
New York
$146K +$191K +35,440 New
JP Morgan Chase
88
JP Morgan Chase
New York
$139K +$182K +33,764 New
BNP Paribas Financial Markets
89
BNP Paribas Financial Markets
France
$138K +$181K +33,622 New
D.E. Shaw & Co
90
D.E. Shaw & Co
New York
$124K +$162K +30,054 New
PCM
91
Prelude Capital Management
New York
$117K +$153K +28,418 New
QI
92
Quotient Investors
New York
$110K +$144K +26,700 New
UBS AM
93
UBS AM
Illinois
$108K +$141K +26,200 New
LOM
94
Loeb Offshore Management
New York
$103K +$134K +25,000 New
SCA
95
SAC Capital Advisors
Connecticut
$87K +$113K +21,079 New
Two Sigma Advisers
96
Two Sigma Advisers
New York
$71K +$93K +17,291 New
PA
97
Pinnacle Associates
New York
$64K +$83.3K +15,500 New
AL
98
Airain Ltd
Guernsey
$62K +$80.9K +15,046 New
BJ
99
BlackRock Japan
Japan
$62K +$81.6K +15,177 New
RA
100
Royce & Associates
New York
$51K +$66.1K +12,300 New
1 2 3
4
5

ASTX Hedge Fund Activity: Q2 2013 in Review

120 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in ASTEX PHARMACEUTICALS, INC COM (ASTX) for Q2 2013, worth a combined $214M.

Buyers outnumbered sellers: 120 funds opened new ASTX positions and 0 closed out — a net gain of 120 holders — while 0 added to existing stakes and 0 trimmed.

  • 120 institutional investors held ASTEX PHARMACEUTICALS, INC COM (ASTX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $214M of ASTEX PHARMACEUTICALS, INC COM stock for Q2 2013.
  • 120 funds opened new ASTEX PHARMACEUTICALS, INC COM positions in Q2 2013 and 0 closed out, a net change of +120 holders.

Based on aggregated 13F filings for Q2 2013.